XTL Biopharmaceuticals Ltd.
NASDAQ Capital MarketTotal Valuation
XTL Biopharmaceuticals Ltd. carries a market capitalization of 6.91M, placing it among publicly traded companies globally.
| Market Cap | 6.91M |
| Enterprise Value | N/A |
Share Statistics
XTL Biopharmaceuticals Ltd. currently has 881.39M shares outstanding.
| Shares Outstanding | 881.39M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 24.53, and the price-to-book ratio stands at -0.08.
| PE Ratio | N/A |
| PS Ratio | 24.53 |
| PB Ratio | -0.08 |
| P/TBV Ratio | -7.03 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
XTL Biopharmaceuticals Ltd. maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.61 |
| Quick Ratio | 0.59 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -77.57 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -18.71 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 0.19 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
XTL Biopharmaceuticals Ltd.'s stock has declined approximately -59.44444% over the past 52 weeks. The 50-day moving average sits at 2.59, while the 200-day moving average is 3.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | -59.44444% |
| 50-Day Moving Average | 2.59 |
| 200-Day Moving Average | 3.24 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, XTL Biopharmaceuticals Ltd. generated 451,000.00 in revenue and converted that into -1.03M in net income, yielding earnings per share of -0.75. EBITDA reached -2.17M, while operating income came in at -2.17M.
| Revenue | 451,000.00 |
| Gross Profit | -43,000.00 |
| Operating Income | -2.17M |
| Pretax Income | -1.16M |
| Net Income | -1.03M |
| EBITDA | -2.17M |
| EBIT | -2.17M |
| Earnings Per Share (EPS) | -0.75 |
Balance Sheet
Total book value stands at -135.87M, with working capital of -867,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.14M |
| Total Debt | N/A |
| Net Debt | -233,000.00 |
| Equity (Book Value) | -135.87M |
| Book Value Per Share | -99.74 |
| Working Capital | -867,000.00 |
Margins
XTL Biopharmaceuticals Ltd. operates with a gross margin of 26.39, reflecting its pricing power and cost economics. The operating margin of -481.60 and net profit margin of -227.72 provide insight into operational efficiency.
| Gross Margin | 26.39 |
| Operating Margin | -481.60 |
| Pretax Margin | -256.54 |
| Profit Margin | -227.72 |
| EBITDA Margin | -481.60 |
Stock Splits
XTL Biopharmaceuticals Ltd.'s most recent stock split took place on March 25, 2026 with a 4:1 split ratio.
| Last Split Date | 3/25/2026 |
| Split Ratio | 4:1 |
Scores
XTL Biopharmaceuticals Ltd. posts an Altman Z-Score of -147.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -147.36 |